Phytopharm
| Pharmaceutical | |
| Defunct | 14 October 2013[1] |
| Headquarters | Huntingdon, United Kingdom |
Area served | Pharmaceuticals |
Phytopharm was a pharmaceutical company based in the United Kingdom. According to the company's website, its lead products were Cogane and Myogane, which are members of the sapogenin class of compounds. It was listed on the London Stock Exchange and was a constituent of the FTSE Fledgling Index.
The company collapsed following failure of its main drug during clinical trials.[2] It is now named Ixico.[3]
References
- ↑ "Phytopharm shareholders approve IXICO acquisition". 14 October 2013. Retrieved 9 December 2014.
- ↑ "Phytopharm says Cogane Phase II trials disappoint". 18 February 2013. Retrieved 9 December 2014.
- ↑ http://www.londonstockexchange.com/exchange/prices-and-markets/stocks/new-and-recent-issues/new-recent-issue-details.html?issueId=8901
See also
External links
This article is issued from Wikipedia - version of the 10/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.